CSTL Castle Biosciences

Castle Biosciences Celebrates Skin Cancer Awareness Month

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, recognizes the importance of Skin Cancer Awareness Month and is proud to continue its ongoing collaboration with The Sun Bus and The Skin Cancer Foundation in support of skin cancer prevention, research, education and advocacy.

“At our core, we are passionate about transforming disease management, improving health and making a meaningful difference in the lives of those affected by skin cancer,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “Skin Cancer Awareness Month provides an opportunity to reaffirm our commitment to improving patient care through our partnerships with patient-focused organizations who enable us to broaden our impact on the patient communities we serve and promote the importance of prevention, early detection and optimized treatment.”

Skin cancer is the most common cancer worldwide, and in the U.S., more people are diagnosed with skin cancer each year than all other cancers combined.1 Observed each May, Skin Cancer Awareness Month aims to increase general disease awareness and educate the public on ways to prevent, detect and treat skin cancer. Castle’s innovative tests are designed to help improve the care of patients with skin cancer by providing personalized information based on the individual biology of their tumor.

The Sun Bus

As a platinum sponsor, Castle is proud to support The Sun Bus for the third consecutive year. Launched by the Colorado Melanoma Foundation in 2019, The Sun Bus is a mobile clinic and classroom that provides free skin screenings, skin cancer awareness and sun safety education to residents across several southwestern states in the U.S.

“While skin cancer is the most commonly diagnosed cancer in the U.S., it is also one of the most preventable,” said Tamara Terzian, Ph.D., executive director of The Sun Bus. “Through a focus on education and community outreach, and the generous support of our sponsors, like Castle Biosciences, we are able to spread this message to thousands of people each year on our U.S. tours.”

The Sun Bus launched its 2023 tour in April and will make multiple stops during its nine-state tour before wrapping up in November.

The Skin Cancer Foundation

This marks the second consecutive year that Castle has collaborated with The Skin Cancer Foundation on key educational programs as well as the Foundation’s signature fundraising event in New York City, the annual Champions for Change Gala.

“We are thankful for Castle Biosciences’ ongoing commitment to The Skin Cancer Foundation,” said Dan Latore, executive director of The Skin Cancer Foundation. “Their support enables our educational campaigns, community programs and research initiatives. Together, we are making a difference in people’s lives, and that is what matters the most.”

About The Sun Bus

The Sun Bus is a mobile clinic that offers a sun safety education experience that hyper-targets select audiences at varying times throughout the year. The program was launched by the Colorado Melanoma Foundation in 2019 in an effort to better address their mission of bringing free skin exams and public education to its Colorado residents. Since then, it has expanded its tour to reach nine states, and its combined 2021 and 2022 efforts achieved the following milestones: more than 4,156 Sun Bus visitors were screened for skin cancer by 133 volunteer physicians over 93 total days across Texas, Georgia, Missouri, Iowa, Kansas, Wyoming, Colorado, New Mexico and Arizona. These screenings resulted in 2,181 referrals for follow-up of a suspicious mole or other skin lesion.2 For more information and a calendar of tour locations, visit .

About The Skin Cancer Foundation

The Skin Cancer Foundation saves and improves lives by empowering people to take a proactive approach to daily sun protection and the early detection and treatment of skin cancer. The Foundation seeks to decrease the incidence of skin cancer through public and professional education and research. Since its inception in 1979, the Foundation has recommended following a complete sun protection strategy that includes seeking shade and covering up with clothing, including a wide-brimmed hat and UV-blocking sunglasses, in addition to daily sunscreen use. For more information, visit .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

1. The Skin Cancer Foundation; ; accessed May 26, 2023

2. The Sun Bus; ; accessed May 26, 2023

EN
30/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports ...

 PRESS RELEASE

Castle Biosciences Announces Grand Opening of New Corporate Headquarte...

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...

 PRESS RELEASE

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year...

 PRESS RELEASE

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ ...

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (N...

 PRESS RELEASE

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financ...

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 FRIENDSWOOD, Texas, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the fourth quarter and year ended Dec. 31, 2025, after the close of market on Thursday, Feb. 26, 2026. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch